Stocks Market
Sothema Wins AMMC Clearance for 630 Million Dirham Capital Raise
The Moroccan Capital Market Authority (AMMC) has signed off the prospectus for Sothema’s new capital increase, involving a 630 million dirham transaction in exchange for Soludia Maghreb shares. The issuance of 406,728 new shares at a subscription price of 1,550 dirhams will become effective on December 15, 2025, completing a significant ownership swap. This approval marks a pivotal moment for Sothema as it consolidates its position in the therapeutic sector and rewards its partners, Abdellaziz Razkaoui and Capital Mezzanine III.
Listen to this article
Unlock audio versions of premium articles and more with a Pro subscription.
Key Highlights
- Capital Increase: 630 million dirhams.
- New Shares: 406,728 at 1,550 dirhams each.
- Nominal Value: 50 dirhams per share.
- Effective Date: 15 December 2025.
- Strategic Partners: Abdellaziz Razkaoui & Capital Mezzanine III.
The Moroccan Capital Market Authority (AMMC) announced on Tuesday that it has approved the prospectus for Sothema’s capital increase, conducted via a nature contribution. The transaction involves exchanging Soludia Maghreb shares for newly issued shares in Sothema.
Under the deal, the company will issue 406,728 new shares, each priced at 1,550 dirhams and carrying a nominal value of 50 dirhams. The total capital injection amounts to roughly 630.43 million dirhams, a substantial boost for the therapeutic company.
Acting on behalf of Abdellaziz Razkaoui and Capital Mezzanine III, Sothema has agreed to allocate the funds received in return for a share swap of Soludia Maghreb titles. The transaction is scheduled to be executed on 15 December 2025.
AMMC’s approval comes as part of its ongoing efforts to strengthen the Moroccan capital market and support strategic corporate restructuring. This move also signals Sothema’s intent to consolidate its market presence and reward its partners.
Implications for Inversors
Investors should note that the new shares will become available for trading following the effective date. The capital increase is expected to improve liquidity and enhance the company’s balance sheet, potentially driving future growth initiatives in the pharmaceutical sector.